14JUN

UK grant count falls to 10-year low

2 min read

16:35UTC

Fewer companies are receiving grants even as average grant size rises. The money is concentrating upward, leaving proof-of-concept founders with fewer options.

← Back to London startup raises Britain's own AI model Jump to analysis ↓

TechnologyDeveloping

Key takeaway

Grant count is at a decade low; proof-of-concept funding is harder to find than at any point since 2016.

Beauhurst's 2026 spinout report shows UK grant awards fell to their lowest count since 2016, even as the average grant size rose 10.96% to £423,000 ¹. Fewer companies are receiving larger awards. The total grant pool is not collapsing, but its distribution is shifting toward mid-stage companies that can absorb bigger tickets.

For a university team seeking a small grant to test an early hypothesis, the narrowing is material. Proof-of-concept funding sits below the threshold of most state programmes. The new Innovate UK Velocity model favours companies with demonstrated team capability and technical breakthrough; by definition, the earliest-stage ventures cannot yet demonstrate either. The expanded £40m proof-of-concept fund (up from £20m over three years) partially addresses the gap but does not restore the volume of small grants available a decade ago.

All of this is happening while the government deploys growth-stage capital at record scale through the British Business Bank, the Sovereign AI Unit, and sector-specific funds. Almost all of it targets companies that have already survived the earliest stages. The pipeline that feeds those programmes is quietly thinning at its base.

Deep Analysis

In plain English

The UK gave out fewer research and development grants to startups and spinouts in 2025 than at any point since 2016. But each individual grant was larger on average (£423,000). The total money spent on grants may not have fallen much, but fewer companies are receiving any grant at all. This matters most for very early-stage companies that need a small amount of money (£50,000 to £200,000) to test whether their idea works before raising investment. These companies are the least served by larger grants to fewer recipients.

What could happen next?

Consequence
UK university spinouts requiring £50k-£200k proof-of-concept funding face a widening gap as grant counts fall and Innovate UK shifts to portfolio selection of more advanced companies.

Source Landscape

This story draws on neutral-leaning sources

Primary parallel: The UK's Technology Strategy Board (TSB, predecessor to Innovate UK) ran Collaborative R&D competitions from 2007 with explicit targets for grant distribution breadth. At peak in 2011-12, TSB distributed approximately 3,000 grants per year.

The subsequent consolidation under UKRI reduced competition frequency and increased average award size, beginning the count decline that Beauhurst now measures at a 10-year low. The structural pattern is deliberate policy concentration, not market contraction.

Counter-parallel: Germany's EXIST programme (part of the Federal Ministry for Economic Affairs) has maintained consistent grant count levels since 2007 by separating proof-of-concept grants (EXIST-Forschungstransfer, small, broad) from scale-up grants (EXIST-Gründerstipendium, larger, selective). The UK has no equivalent structural separation, which means rising average grant size mechanically excludes early proof-of-concept applicants.

Consensus view: Beauhurst's longitudinal tracking and the University of Cambridge's Centre for Business Research (CBR) both find that pre-seed spinout funding gaps are among the most persistent structural failures in UK innovation finance.

The Beauhurst 2026 data showing fewest grants since 2016 despite a rising average grant size is consistent with a deliberate policy shift toward concentrating grants in companies with higher technical readiness levels, which excludes early proof-of-concept work.

Counter-view: The Wellcome Trust's analysis of UK biomedical spinout funding (2025) argues that falling grant counts reflect improving quality rather than contracting supply: universities are producing fewer but more commercially viable spinouts because technology transfer offices have become more selective. On this reading, lower grant counts correlate with higher eventual spinout success rates.

Key tension: Whether the decline in grant count reflects a deliberate and beneficial quality filter, or a funding gap at proof-of-concept stage that will reduce the number of spinouts that reach the commercial readiness threshold for any funding at all.

Sources:Beauhurst / Penningtons Manches Cooper·Beauhurst / Penningtons Manches Cooper

Mentions:Beauhurst →Sovereign AI Unit →British Business Bank →Prima →Innovate UK →Germany →Cambridge →UKRI →

First Reported In

Update #1 · State capital floods in, seed money drains

Beauhurst / Penningtons Manches Cooper· 13 Apr 2026

Read original →

Causes and effects

This Event

UK grant count falls to 10-year low

Declining grant volume squeezes the earliest stage of the UK startup pipeline at the same moment growth-stage capital is most abundant.

Led to

EMI reform quadruples the scaleup thresholds

EMI reform targets scaleups while grant award counts are already at a 10-year low (ID:2351), highlighting a structural gap between seed and scaleup-tier instruments.

Occurred 6 Apr 2026

Read story →

Different Perspectives

European VC (Atomico, Plural, Highland Europe as PhysicsX / Lumen adjacents)

European growth funds have backed three of the week's largest UK rounds via follow-on positions and co-investments; the PhysicsX cap table includes Atomico (European-domiciled, Skype-founded) and Siemens (German industrial), both returning investors who view UK physical-AI as a supply-chain multiplier across Continental manufacturing. European LP capital is filling the growth tier UK state vehicles have not yet reached.

UK regulated-industry coalition (Lloyds, BAE Systems, LSEG via Lumen Sovereign)

Thirteen of Britain's most heavily regulated companies backed Cosine not as a philanthropic gesture but to acquire a data-compliant AI tool that replaces costly US API alternatives; each partner provides proprietary data in exchange for early access. Their participation signals that regulated incumbents, not venture funds, may be the structural customer base that sustains the UK's sovereign model tier.

US growth investors (General Catalyst, Intrepid Growth Partners)

US and allied growth investors followed Temasek into PhysicsX's Series C; General Catalyst also returned in the round after backing Geordie the previous week. The absence of any US-led domestic-capital equivalent is a structural reading: American funds enter at growth stage where returns are clearest, ceding seed and Series A economics to UK vehicles that are themselves contracting.

Temasek (Singapore sovereign fund)

Temasek led PhysicsX's $300m Series C, its second major UK deep-tech cheque in six weeks after co-investing in Isomorphic's Series B with the SAIU; its thesis runs through Southeast Asian advanced-manufacturing adjacencies, not bilateral UK policy. Singapore's sovereign capital is now the default lead for British scale-ups above £200m that fall outside the BBB's priority sectors.

UK Government (DSIT / Liz Kendall)

DSIT published its first sector scorecard on 10 June setting a £8.3bn 2025 baseline, and the Sovereign AI Unit's compute allocation enabled Cosine's Lumen Sovereign launch. The scorecard's own barbell figure, more capital in fewer rounds, exposes the policy gap DSIT has not yet addressed: no instrument currently leads venture rounds in industrial AI simulation sectors.

Spanish state finance (COFIDES, CDTI)

Spain's COFIDES and CDTI have co-invested alongside UK deep-tech rounds in prior cycles and track the British Business Bank's direct-investment activity as a benchmark for state-capital deployment in innovation. BBB's two direct co-investments in one week set a pace reference for Iberian equivalents.